ArticleNeurology open access2026
Association of Circulating Vitamin D in Midlife With Increased Tau-PET Burden in Dementia-Free Adults.
Article in Neurology open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background and Objectives: Low circulating vitamin D in later-life has been associated with increased risk of cognitive impairment and clinical dementia. However, whether serum vitamin D in early mid-life is associated with neuroimaging markers of preclinical dementia is unknown. We aimed to determine the association between early mid-life serum vitamin D and subsequent tau- and amyloid- burden on brain-PET, in a cohort of dementia-free adults. Methods: This was a prospective cohort study of Framingham Heart Study Generation 3 cohort participants who were dementia-free at time of PET, had serum 25-hydroxyvitamin D [25(OH)D] measured at examination cycle 1 (2002-2005) and had available 11C-Pittsburgh Compound-B (PiB)- and/or 18F-Flortaucipir (FTP)-PET completed between 2016 and 2019. Outcomes included global tau-PET deposition (across all 34 FreeSurfer defined cortical regions), composite tau (those regions most susceptible to early tau involvement in AD dementia, namely entorhinal cortex, parahippocampal gyrus, fusiform gyrus, amygdala and inferior and middle temporal cortices) and amyloid-PET deposition (composite region including the frontal, lateral temporal, parietal and retrosplenial cortices [FLR]). Data were analyzed using multivariable linear regression models adjusted for age, sex, time from blood sampling to PET, PET camera type, depression, season, current smoking, systolic blood pressure, use of antihypertensive medication, diabetes mellitus, cardiovascular disease, and body mass index. Results: In our sample (n= 793, 53% women, mean age 39±8years) with available serum 25(OH)D and amyloid (n=424) and/or tau-PET (n=369), the mean time between blood sampling and PET was 16±2 years. On multivariable linear regression analysis, higher serum 25(OH)D was associated with lower global (β= -0.022; 95% CI: -0.040 to -0.004; p = 0.010]) and composite tau-PET deposition (β= -0.023; 95% CI: -0.043 to -0.003; p = 0.016]),but was not associated with amyloid-PET burden. Discussion: In a group of dementia-free individuals, higher serum 25(OH)D at early mid-life was associated with lower tau deposition on brain PET a mean of 16 years later. Low vitamin D in mid-life may represent a potentially modifiable target to mitigate the risk of neuroimaging signs of preclinical dementia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.